Cargando…

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome

AIM: To report an analysis of ~1 year of setmelanotide treatment for obesity and hunger, as well as metabolic and cardiac outcomes, in individuals with Bardet‐Biedl syndrome (BBS). MATERIALS AND METHODS: Individuals aged 12 years and older with BBS received once‐daily setmelanotide. The dose was tit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haws, Robert, Brady, Sheila, Davis, Elisabeth, Fletty, Kristina, Yuan, Guojun, Gordon, Gregory, Stewart, Murray, Yanovski, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689750/ https://www.ncbi.nlm.nih.gov/pubmed/32627316 http://dx.doi.org/10.1111/dom.14133

Ejemplares similares

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
por: Haws, Robert M., et al.
Publicado: (2021)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
por: Ervin, Claire, et al.
Publicado: (2023)

Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet–Biedl syndrome: phase 3 trial results
por: Forsythe, Elizabeth, et al.
Publicado: (2023)

Kidney failure in Bardet–Biedl syndrome
por: Meyer, Jennifer R., et al.
Publicado: (2022)

Bardet‐Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome
por: Pomeroy, Jeremy, et al.
Publicado: (2020)

Bardet–Biedl Syndrome in an Ethiopian
por: Tsegaw, Asamere, et al.
Publicado: (2021)

Sleep and physical activity patterns in adults and children with Bardet–Biedl syndrome
por: Pomeroy, Jeremy, et al.
Publicado: (2021)

Bardet-Biedl and Alström syndromes in Spain
por: Valverde, D, et al.
Publicado: (2012)

Bardet–Biedl syndrome: beyond the cilium
por: Tobin, Jonathan L., et al.
Publicado: (2007)

Bardet–Biedl Syndrome Presenting in Adulthood
por: Ankleshwaria, Chinmay, et al.
Publicado: (2022)

Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis
por: Ferraz Barbosa, Bárbara, et al.
Publicado: (2023)

Managing Bardet–Biedl Syndrome—Now and in the Future
por: Forsythe, Elizabeth, et al.
Publicado: (2018)

A rare case of Bardet–Biedl syndrome
por: Shrinkhal,, et al.
Publicado: (2019)

Laurence-moon-biedl-bardet syndrome: An overview
por: Rissardo, Jamir Pitton, et al.
Publicado: (2020)

Bardet–Biedl syndrome: a case series
por: Elawad, Omer Ali Mohamed Ahmed, et al.
Publicado: (2022)

Bangladeshi Case Series of Bardet–Biedl Syndrome
por: Osman, Fariah, et al.
Publicado: (2023)

Laurence-Moon-Bardet Biedl Syndrome With Cholelithiasis
por: Kaleem, Safa, et al.
Publicado: (2023)

Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022)

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
por: Collet, Tinh-Hai, et al.
Publicado: (2017)

A rare case of obesity. Can it be Bardet‐Biedl Syndrome?
por: Shrestha, Sandeep, et al.
Publicado: (2019)

Genetic predictors of cardiovascular morbidity in Bardet–Biedl syndrome
por: Forsythe, E, et al.
Publicado: (2015)

A Rod-Sparing Retinopathy in Bardet-Biedl Syndrome
por: Chiu, Cynthia S., et al.
Publicado: (2015)

Bardet-Biedl Syndrome with End Stage Renal Disease
por: Parakh, Rajendrakumar, et al.
Publicado: (2016)

Reproduction Function in Male Patients With Bardet Biedl Syndrome
por: Koscinski, Isabelle, et al.
Publicado: (2020)

Proteomic and Transcriptomic Landscapes of Alström and Bardet–Biedl Syndromes
por: Smyczynska, Urszula, et al.
Publicado: (2022)

Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook
por: Melluso, Andrea, et al.
Publicado: (2023)

Burden of hyperphagia and obesity in Bardet–Biedl syndrome: a multicountry survey
por: Forsythe, Elizabeth, et al.
Publicado: (2023)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype
por: Kamermans, Alwin, et al.
Publicado: (2019)

Computational and Structural Analysis to Assess the Pathogenicity of Bardet-Biedl Syndrome Related Missense Variants Identified in Bardet-Biedl Syndrome 10 Gene (BBS10)
por: Gupta, Neha, et al.
Publicado: (2022)

Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling
por: Seo, Seongjin, et al.
Publicado: (2009)

Visual acuity and retinal function in patients with Bardet-Biedl syndrome
por: Berezovsky, Adriana, et al.
Publicado: (2012)

Regulation of Insulin Receptor Trafficking by Bardet Biedl Syndrome Proteins
por: Starks, Rachel D., et al.
Publicado: (2015)

Bardet-Biedl syndrome presenting with steroid sensitive nephrotic syndrome
por: Singh, K. K., et al.
Publicado: (2015)

Bardet–Biedl syndrome: Genetics, molecular pathophysiology, and disease management
por: Priya, Sathya, et al.
Publicado: (2016)

The Laurence-Moon-Bardet-Biedl Syndrome. Report of Two Cases
por: Rao, K. Someswara
Publicado: (1950)

Toni Mochty: Bardet Biedl syndrome “avant la lettre”
por: de Herder, Wouter
Publicado: (2020)

Laurence-Moon-Bardet-Biedl Syndrome: A Case Report
por: Khan, Bilal Ahmed, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fjl9c4j5cdq0uqiq65o5lj2dv7